It was widelyaccepted that use of ACE inhibitors or ARB blockers were equivalent in their protection of kidneys in diabetic nephropathy.
Recently the thinking has been changing.It has been shown in animal experiments that LOSARTAN decreases tranforming growth factor beta and this MAY be benefical.
Since LOSARTAN has become generic in US it is worthwhile placing patients on it as the drug of first choice.
In order to do controlled trail head to head comparison with ACE inhibitors will require large number of patients and prolonged follow up.
Maybe Cochrane review will publish a article.